SNT · ASX

Syntara Limited (ASX:SNT)

AU$0.034

 0.0 (0.0%)
ASX:Live
10/10/2025 03:58:22 PM
HALO Ords HALO Consensus Value GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

SNT Overview

SNT Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Weak

GARP

Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Strong

Earnings

Neutral

Growth

Earnings

Strong

Dividends

Very Weak

Quality

Capital Efficiency

Very Weak

Balance Sheet

Very Weak

About SNT

Website

Syntara Limited

Telephone

61.2.8760.1480

Address

Unit 2 Frenchs Forest 20 Rodborough Road Sydney, New South Wales (NSW) 2086

Description

Syntara Ltd. is a clinical stage drug development company which engages in the development of healthcare products for haematological diseases. Its lead compounds include amsulostat (SNT-5055) and topical pan-LOX inhibitors with SNT-9495. The company was founded by Brett Charlton and William B. Cowden on May 29, 1998 and is headquartered in Sydney, Australia.

SNT Price Chart

Key Stats

Market Cap

AU$55.50M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.02 - 0.09

Trade Value (12mth)

AU$83,677.00

1 week

-2.86%

1 month

41.67%

YTD

-56.96%

1 year

-20.93%

All time high

4.31

Key Fundamentals

EPS 3 yr Growth

58.80%

EBITDA Margin

N/A

Operating Cashflow

-$11m

Free Cash Flow Return

-107.00%

ROIC

-118.00%

Interest Coverage

-648.30

Quick Ratio

3.90

Other Data

Shares on Issue (Fully Dilluted)

1625m

HALO Sector

Healthcare

Next Company Report Date

02-Sep-26

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

SNT Announcements

Latest Announcements

Date Announcements

02 October 25

Notification regarding unquoted securities - SNT

×

Notification regarding unquoted securities - SNT

01 October 25

Notice under ASX Listing Rule 3.13.1

×

Notice under ASX Listing Rule 3.13.1

30 September 25

Appoints global myelofibrosis experts to support amsulostat

×

Appoints global myelofibrosis experts to support amsulostat

30 September 25

Positive top-line Phase 2a data confirms competitive profile

×

Positive top-line Phase 2a data confirms competitive profile

30 September 25

Positive final Phase 2a amsulostat data webinar presentation

×

Positive final Phase 2a amsulostat data webinar presentation

24 September 25

Receives A$5.6m R&D Tax Incentive

×

Receives A$5.6m R&D Tax Incentive

09 September 25

Investor Presentation E&P Small Cap Healthcare Conference

×

Investor Presentation E&P Small Cap Healthcare Conference

01 September 25

Letter to shareholders - path forward for amsulostat

×

Letter to shareholders - path forward for amsulostat

28 August 25

Application for quotation of securities - SNT

×

Application for quotation of securities - SNT

28 August 25

Preliminary Final Report

×

Preliminary Final Report

28 August 25

Annual Report to shareholders

×

Annual Report to shareholders

28 August 25

Appendix 4G Key to Disclosures

×

Appendix 4G Key to Disclosures

28 August 25

2025 Corporate Governance Statement

×

2025 Corporate Governance Statement

19 August 25

TechKnow Investor Presentation

×

TechKnow Investor Presentation

11 August 25

Guidance from FDA on amsulostat clinical progression

×

Guidance from FDA on amsulostat clinical progression

11 August 25

FDA guidance webinar

×

FDA guidance webinar

08 August 25

Application for quotation of securities - SNT

×

Application for quotation of securities - SNT

04 August 25

Notification regarding unquoted securities - SNT

×

Notification regarding unquoted securities - SNT

04 August 25

Proposed issue of securities to the CEO

×

Proposed issue of securities to the CEO

04 August 25

Reinstatement to Quotation

×

Reinstatement to Quotation

01 August 25

Quarterly Appendix 4C Cash Flow Report

×

Quarterly Appendix 4C Cash Flow Report

01 August 25

Appendix 4C quarterly webinar

×

Appendix 4C quarterly webinar

01 August 25

Suspension from Quotation

×

Suspension from Quotation

01 August 25

Quarterly update webinar presentation

×

Quarterly update webinar presentation

30 July 25

Quarterly Shareholder Report

×

Quarterly Shareholder Report

SNT Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.02 -0.02 -0.01 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.02 -0.02 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -408.8 -26.6 75.3 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.01 -0.01 -0.01 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.01 -0.02 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 46.1 -25.3 48.9 Lock Lock Lock
     Yield % Lock Lock Lock Lock -23.1 -63.2 -14.3 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.01 0.00 0.01 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.01 0.00 0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -30.7 -69.4 158.4 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 656 955 1,469 Lock Lock Lock
Basic m Lock Lock Lock Lock 656 955 1,469 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -100.0 N/A N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 18 18 19 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -2 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock 72.0 87.4 3.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -18 -18 -19 Lock Lock Lock
     Growth % Lock Lock Lock Lock -7.9 -2.6 -5.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 2 0 0 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -20 -19 -20 Lock Lock Lock
     Growth % Lock Lock Lock Lock 0.4 5.8 -5.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -19 -18 -18 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -5 -5 -6 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -11 -21 -8 Lock Lock Lock
     Growth % Lock Lock Lock Lock -486.8 -84.2 62.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -7 -14 -11 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 1 4 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 7 7 18 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -7 -14 -11 Lock Lock Lock
     Growth % Lock Lock Lock Lock 54.1 -95.4 23.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 9 4 15 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 24 10 21 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 6 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -1 -3 -15 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 14 6 5 Lock Lock Lock
Equity $m Lock Lock Lock Lock 10 5 16 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 16 5 16 Lock Lock Lock
     Growth % Lock Lock Lock Lock 21.5 -70.0 236.2 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -47.3 -201.5 -36.9 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -118.8 -447.1 -49.4 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -120.2 -220.1 -183.1 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -92.8 -190.8 -118.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -50.3 -202.2 -107.0 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
Leverage
Interest Cover X Lock Lock Lock Lock -80.7 -47.8 -648.3 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.0 0.2 0.8 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -9.1 -60.2 -93.6 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 2.3 1.8 3.9 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 2.1 1.8 3.9 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 49.4 36.0 71.9 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -90.6 -265.7 -208.2 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.9 0.3 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -47.3 -201.5 -36.9 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 2.5 2.2 1.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -118.8 -447.1 -49.4 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -118.8 -447.1 -49.4 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 392.8 1,290.9 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 392.8 1,290.9 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 217.0 0.0 2,563.2 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 175.9 1,290.9 -2,563.2 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.08%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

0.10%

3 Month Change

0.10%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

SNT Shortsell

Frequently Asked Questions

The current share price of Syntara Limited (SNT:ASX) is AU$0.034.
The 52-week high share price for Syntara Limited (SNT:ASX) is AU$0.09.
The 52-week low share price for Syntara Limited (SNT:ASX)? is AU$0.02.
Syntara Limited (SNT:ASX) does not pay a dividend.
Syntara Limited (SNT:ASX) does not pay a dividend.
Syntara Limited (SNT:ASX) has a franking level of 0.0%.
Syntara Limited (SNT:ASX) is classified in the Healthcare.
The current P/E ratio for Syntara Limited (SNT:ASX) is .
The current share price of Syntara Limited (SNT:ASX) is AU$0.034.
The 52-week high share price for Syntara Limited (SNT:ASX) is AU$0.09.
The 52-week low share price for Syntara Limited (SNT:ASX)? is AU$0.02.
Syntara Limited (SNT:ASX) does not pay a dividend.
Syntara Limited (SNT:ASX) does not pay a dividend.
Syntara Limited (SNT:ASX) has a franking level of 0.0%.
Syntara Limited (SNT:ASX) is classified in the Healthcare.
The current P/E ratio for Syntara Limited (SNT:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox
App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.

Ff